You Position: Home > Paper
Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray
( views:262, downloads:114 )
- Author:
- No author available
- Journal Title:
- ACTA PHARMACEUTICA SINICA
- Issue:
- 8
- DOI:
- 10.3321/j.issn:0513-4870.2005.08.005
- Key Word:
- 甲苯磺丁脲;细胞色素P450 CYP2C9;等位基因;单核苷酸多态性;基因分型
Abstract： 目的研究细胞色素P450 CYP2C9基因多态性对甲苯磺丁脲代谢动力学的影响.方法用基因芯片对137名健康志愿者进行CYP2C9基因多态性检测,将受试者分为CYP2C9野生型、杂合突变型和纯合突变型3组,用高效液相色谱法检测甲苯磺丁脲在受试者体内的药物代谢动力学参数,统计分析各组间药代动力学性质差异.结果在137名受试者中发现了9个CYP2C9*1/*3杂合型突变体和1个CYP2C9*3/*3纯合型突变体,其余为野生型个体.将9名CYP2C9*1/*3,1名CYP2C9*3/*3以及随机抽取的10名野生型个体分组,以甲苯磺丁脲为探药进行药物代谢动力学研究.结果在杂合型突变个体组以及纯合型突变个体组中,甲苯磺丁脲的代谢率显著低于对照的野生型个体组.结论 CYP2C9基因多态性对甲苯磺丁脲代谢具有显著影响并呈基因剂量效应,检测突变型个体对指导临床合理用药和个体化医疗具有重要意义.
- [1]Si-Yuan Wen,Hui WANG,Ou-Jun Sun,etc.Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray[J].2003,(6).
- [2]Scordo MG,Spina E,Brandolese R,etc.Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.[J].2001,70(4).
- [3]Kim RB,Kneller MB,Wilkinson GR,etc.Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.[J].2001,60(2).
- [4]Straughn AB,Blaisdell J,Goldstein JA,etc.Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.[J].1999,9(1).
- [5]Lee CR,Goldstein JA,Pieper JA.Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.[J].2002,12(3).
- [6]Gaedigk A,Nafziger AN,Bertino-JS Jr,etc.Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.[J].2001,41(7).
- [7]King BP,Daly AK.Pharmacogenetics of oral anticoagulants.[J].2003,13(5).
- [8]Buchman TG,Zehnbauer BA,McGrath S,etc.Cytochrome P450 polymorphisms are associated with reduced warfarin dose.[J].2000,128(2).
- [9]Perrett J,Plume J,Aherne Z,etc.Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.[J].2004,57(2).
- [10]Ann K, Daly,Christopher P, Day,Guruprasad P, Aithal.CYP2C9 polymorphism and warfarin dose requirements.[J].2002,53(4).
- [11]Rohde W,Meisel C,Roots I,etc.Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.[J].2004,43(4).
- [12]Leif Bertilsson.Geographical/Interracial Differences in Polymorphic Drug OxidationCurrent State of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19[J].1995,29(3).
- [13]Shon JH,Kim MK,Park JY,etc.Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.[J].2001,51(3).